At a glance
- Originator Merck & Co
- Class Immunotherapies
- Mechanism of Action Calcineurin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cryptococcosis
Most Recent Events
- 19 Jun 2001 No-Development-Reported for Cryptococcosis in USA (Unknown route)
- 14 Aug 1997 New profile
- 14 Aug 1997 Preclinical development for Cryptococcosis in USA (Unknown route)